OR WAIT null SECS
The new offering, designed to enhance diabetes trials, combines wearable technology with Quintiles' therapeutic and analytical expertise.
Quintiles announced a new service offering designed to improve diabetes-focused clinical trials. Through the solution, continuous glucose measurements will be monitored by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. In the clinical trial setting, such comprehensive and timely glucose visibility can potentially improve patient safety, accelerate clinical development, and provide a basis for differentiated claims.
Read the full release here